At Hisun USA, our goal is to create a broad portfolio of generics through leveraging the diverse and expansive capabilities of our parent company while actively seeking to acquire products, technologies or companies with strategic value in the US market. With a growing pipeline of oral solid dosage and injectable products, Hisun holds 21 pending ANDAs with many more under development. We are committed to developing and supplying products through our extensive resources and experience:

  • Focus on market and technologically differentiated products
  • Vertically integrated with a well-established API business
  • Proven biopharmaceutical & biosimilar development track record
  • Manufacturing expertise include state-of-the-art facilities, complex development and diverse formulation capabilities

For more information, please contact:

Ginger Collier
Vice President, National Accounts
Hisun Pharmaceuticals USA, Inc.
212 Carnegie Center, Suite 302
Princeton, NJ 08540
Office: 609-275-5055 Ext: 1251 
Email: ginger.collier@hisunusa.com

For Returns: returns@hisunusa.com

For Customer Service: customerservice@hisunusa.com

For Finance: finance@hisunusa.com